December 17, 2020, Coralville, IA – Emmyon is pleased to announce that it has received a new Phase II Small Business Innovation Research (SBIR) award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the U.S. National Institutes of Health (NIH). The funding will support development of novel pharmaceutical compounds for skeletal muscle atrophy, obesity and type 2 diabetes. We’re very grateful to NIAMS and the NIH for their continued support of these efforts.